These vaccines are engineered to encode tumor-associated antigens (TAAs) or patient-specific neoantigens, allowing host antigen-presenting cells to translate the mRNA and present immunogenic epitopes that stimulate robust CD4+ and CD8+ T cell responses against tumor cells (Sun et al., 2023; Sethna et al., 2025). Here, CD8A is linked to neoplasm.